Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 18/20 | 0.76 |
| ▸ | MMP3 | P08254 | 14/20 | 0.76 |
| ▸ | MMP9 | P14780 | 12/20 | 0.76 |
| ▸ | MMP8 | P22894 | 12/20 | 0.76 |
| ▸ | MMP2 | P08253 | 12/20 | 0.76 |
| ▸ | MMP1 | P03956 | 12/20 | 0.76 |
| ▸ | MMP7 | P09237 | 11/20 | 0.76 |
| ▸ | ADAMTS7 | Q9UKP4 | 2/20 | 0.51 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7255895 | 0.86 | MMP13 (1.00) | MMP13MMP3MMP9MMP8MMP2 | |
| SCHEMBL7253917 | 0.84 | MMP13 (0.84) | MMP13MMP3MMP9MMP8MMP2 | |
| SCHEMBL7256353 | 0.83 | MMP13 (0.77) | MMP13MMP3MMP9MMP8MMP2 | |
| SCHEMBL7256569 | 0.81 | MMP13 (0.78) | MMP13MMP3MMP9MMP8MMP2 | |
| SCHEMBL7251430 | 0.79 | MMP13 (1.00) | MMP13MMP3MMP9MMP8MMP2 | |
| SCHEMBL7255921 | 0.79 | MMP3 (0.72) | MMP13MMP3MMP9MMP8MMP2 | |
| SCHEMBL6289713 | 0.78 | MMP13 (0.86) | MMP13MMP3MMP9MMP8MMP2 | |
| SCHEMBL7249791 | 0.77 | MMP13 (0.83) | MMP13MMP3MMP9MMP8MMP2 | |
| SCHEMBL7249949 | 0.77 | MMP13 (0.66) | MMP13MMP3MMP9MMP8MMP2 | |
| SCHEMBL1380370 | 0.76 | MMP2 (0.53) | MMP13MMP3MMP9MMP2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171400-A1 | Heterocyclic side chain containing metalloprotease inhibitors | PROCTER & GAMBLE COMPANY, THE | 2003-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171400-A1 | Heterocyclic side chain containing metalloprotease inhibitors | SERPINB1, ADAM17, TMPRSS15 | MMP13 70/4885MMP3 14/4885MMP9 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.